Publications by authors named "B Arnulf"
Kidney disease is a common complication of monoclonal immunoglobulin (MIg)-secreting B-cell disorders and predominantly occurs in patients who do not meet the criteria for an overt hematological disease. To distinguish this situation from monoclonal gammopathy of undetermined significance, which lacks organ damage, the term monoclonal gammopathy of renal significance (MGRS) was introduced to depict the association of a small, otherwise indolent B-cell clone, with renal disease induced by the secreted MIg. The spectrum of renal disorders in MGRS is wide, encompassing both tubular and glomerular disorders, classified according to the composition of deposits and their ultrastructural pattern of organization.
View Article and Find Full Text PDFInflammation in Waldenström Macroglobulinemia (iWM) predicts outcomes after immuno-chemotherapy and BTK inhibitors, but its origin is unknown. Here, we unravel increased clonal hematopoiesis in iWM patients (61% versus 23% in non-inflammatory WM), suggesting a contribution of environmental cells to iWM.
View Article and Find Full Text PDFArticle Synopsis
- This study evaluated the effectiveness of cardiac magnetic resonance (CMR) imaging compared to other diagnostic markers in predicting mortality in patients with AL cardiac amyloidosis (CA).
- Conducted on 176 patients with a median age of 68 years, the study found that high levels of NT-proBNP and troponin, along with low heart function measurements, were linked to increased mortality risk.
- Extracellular volume (ECV) from CMR emerged as a strong independent predictor of all-cause mortality and heart failure hospitalizations, suggesting it can enhance prognostic assessments beyond the established Mayo Clinic staging.
Outcomes are poor in triple-class-exposed (TCE) relapsed and refractory multiple myeloma (R/RMM). In the phase 3 KarMMa-3 trial, patients with TCE R/RMM and 2 to 4 prior regimens were randomized 2:1 to idecabtagene vicleucel (ide-cel) or standard regimens (SRs). An interim analysis (IA) demonstrated significantly longer median progression-free survival (PFS; primary end point; 13.
View Article and Find Full Text PDF